



Valproic Acid (803): sc-58068

BACKGROUND

Valproic Acid is a fatty acid used as an anticonvulsant and mood-stabilizing drug, mainly for the treatment of epilepsy and bipolar disorder, though it is also used to treat migraine headaches and schizophrenia. Valproic Acid negatively affects the inhibitory neurotransmission function of the neurotransmitter GABA, and it is also an inhibitor of the enzyme histone deacetylase 1 (HDAC1), implicating this drug in neuroprotective HIV therapy. It may function by increasing γ -Aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Common side effects of Valproic Acid include dyspepsia and/or weight gain. Valproic Acid has a molecular weight of 144.211 g/mol and a half life of 9-16 hours. It is an oral drug that is mainly metabolized in the liver to the glucuronide conjugate.

REFERENCES

1. Zona, C. and Avoli, M. 1990. Effects induced by the antiepileptic drug Valproic Acid upon the ionic currents recorded in rat neocortical neurons in cell culture. *Exp. Brain Res.* 81: 313-317.
2. Yamamoto, R., Yanagita, T., Kobayashi, H., Yokoo, H. and Wada, A. 1997. Upregulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic Valproic Acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. *J. Neurochem.* 68: 1655-1662.
3. Tringali, G., Aubry, J.M., Moscianese, K., Zamori, C., Vairano, M., Preziosi, P., Navarra, P. and Pozzoli, G. 2004. Valproic Acid inhibits corticotropin-releasing from the rat hypothalamus *in vitro*: evidence for the involvement of GABAergic neurotransmission. *J. Psychiatry Neurosci.* 29: 459-466.
4. Bailey, D.N. and Briggs, J.R. 2005. Valproic Acid binding to human serum and human placenta *in vitro*. *Ther. Drug Monit.* 27: 375-377.
5. Jin, N., Kovács, A.D., Sui, Z., Dewhurst, S. and Maggirwar, S.B. 2005. Opposite glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. *Neuropharmacology* 48: 576-583.
6. Mongan, N.P. and Gudas, L.J. 2005. Valproic Acid, in combination with all-*trans* retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RAR β 2 in breast cancer cells. *Mol. Cancer Ther.* 4: 477-486.
7. Routy, J.P. 2005. Valproic Acid: a potential role in treating latent HIV infection. *Lancet* 366: 523-524.
8. Shen, W.T., Wong, T.S., Chung, W.Y., Wong, M.G., Kebebew, E., Duh, Q.Y. and Clark, O.H. 2005. Valproic Acid inhibits growth, induces apoptosis, and modulates apoptosis and differentiation gene expression in human thyroid cancer cells. *Surgery* 138: 979-985.
9. Tomasiewicz, H.C., Mague, S.D., Cohen, B.M. and Carlezon, W.A. 2006. Behavioral effects of short-term administration of lithium and Valproic Acid in rats. *Brain Res.* 1093: 83-94.

SOURCE

Valproic Acid (803) is a mouse monoclonal antibody raised against Valproic Acid.

PRODUCT

Each vial contains 100 μ l ascites containing IgG₁ with < 0.1% sodium azide.

APPLICATIONS

Valproic Acid (803) is recommended for detection of Valproic Acid by solid phase ELISA (starting dilution to be determined by researcher, dilution range 1:100-1:5000).

STORAGE

For immediate and continuous use, store at 4° C for up to one month. For sporadic use, freeze in working aliquots in order to avoid repeated freeze/thaw cycles. If turbidity is evident upon prolonged storage, clarify solution by centrifugation.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.